ストックスクリーナーアプリを入手
290.23
0.22%
-0.9291
前日終値:
$291.16
開ける：
$288.93
24時間の取引高:
841.79K
Relative Volume:
0.38
時価総額：
$156.24B
収益：
$34.76B
当期純損益:
$6.62B
株価収益率:
23.74
EPS:
12.223
ネットキャッシュフロー:
$10.61B
1週間 パフォーマンス:
-3.53%
1か月 パフォーマンス:
+6.43%
6か月 パフォーマンス:
+2.62%
1年 パフォーマンス:
-8.40%
1日の値動き範囲:
$288.26
$292.63
1週間の範囲:
$288.26
$302.81
52週間の値動き範囲:
$253.30
$335.88
Amgen Inc Stock (AMGN) Company Profile
AMGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
290.21 | 156.75B | 34.76B | 6.62B | 10.61B | 12.22 |
|
LLY
Lilly Eli Co
|
814.22 | 740.84B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
187.13 | 458.49B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.23 | 402.83B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
123.73 | 250.00B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.07 | 219.80B | 63.43B | 16.42B | 14.72B | 6.4861 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-03 | 再開されました | Raymond James | Mkt Perform |
| 2025-05-20 | 再開されました | Guggenheim | Neutral |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-14 | ダウングレード | Truist | Buy → Hold |
| 2024-09-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | アップグレード | Barclays | Underweight → Equal Weight |
| 2024-05-03 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | アップグレード | Truist | Hold → Buy |
| 2023-10-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-17 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 再開されました | BofA Securities | Neutral |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-04-24 | 繰り返されました | Oppenheimer | Outperform |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 繰り返されました | Truist | Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Underperform |
| 2022-10-31 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2022-10-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-09 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-09 | 繰り返されました | Jefferies | Buy |
| 2022-02-09 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-09 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-09-23 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 開始されました | Daiwa Securities | Buy |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-10-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | アップグレード | Truist | Hold → Buy |
| 2020-10-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | ダウングレード | Truist | Buy → Hold |
| 2020-10-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 再開されました | Guggenheim | Neutral |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-03-30 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-17 | 再開されました | Morgan Stanley | Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-11-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-19 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-05-23 | アップグレード | Citigroup | Neutral → Buy |
すべてを表示
Amgen Inc (AMGN) 最新ニュース
Does Amgen Inc. fit your quant trading modelTrade Exit Summary & Verified Chart Pattern Trade Signals - newser.com
How supply shortages influence Amgen Inc. (AMG) stock2025 Dividend Review & Verified Entry Point Signals - newser.com
Trust Investment Advisors Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Howard Capital Management Inc. Has $5.86 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Motley Fool Asset Management LLC Acquires 2,924 Shares of Amgen Inc. $AMGN - MarketBeat
Logan Capital Management Inc. Reduces Holdings in Amgen Inc. $AMGN - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Has $30.26 Million Position in Amgen Inc. $AMGN - MarketBeat
Will Amgen Inc. (AMG0) stock extend growth storyWeekly Volume Report & Technical Analysis for Trade Confirmation - newser.com
Teacher Retirement System of Texas Sells 8,974 Shares of Amgen Inc. $AMGN - MarketBeat
Transcend Capital Advisors LLC Decreases Stake in Amgen Inc. $AMGN - MarketBeat
Should I buy Amgen Inc. (AMG0) stock before earnings seasonWeekly Trade Review & Daily Chart Pattern Signal Reports - newser.com
What Fibonacci levels say about Amgen Inc. rebound2025 Valuation Update & Fast Exit and Entry Trade Guides - newser.com
Is Amgen Inc. (AMG) stock protected from inflationQuarterly Growth Report & Community Driven Trade Alerts - newser.com
Amgen (AMGN) Expected to Announce Earnings on Tuesday - MarketBeat
Why Amgen Inc. (AMG) stock could be top winnerNew Guidance & Weekly Breakout Opportunity Watchlist - Fundação Cultural do Pará
Using flow based indicators on Amgen Inc.2025 Support & Resistance & Growth Focused Stock Pick Reports - newser.com
What dividend safety score for Amgen Inc. stockEarnings Growth Report & Free Community Consensus Stock Picks - newser.com
What is the fair value estimate for Amgen Inc. (AMG) stock in 2025Weekly Profit Summary & Fast Gain Stock Tips - newser.com
Will Amgen Inc. (AMG0) stock profit from AI boom2025 Market Sentiment & AI Forecast Swing Trade Picks - newser.com
Will Amgen Inc. (AMG0) stock recover faster than industry2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
Amgen’s Promising Phase 3 Study on Blinatumomab for Leukemia: What Investors Need to Know - TipRanks
Amgen’s Long-term Study on Dazodalibep: A Potential Breakthrough for Sjögren’s Syndrome - TipRanks
Amgen’s Phase 2a Study on Autoimmune Diseases: A Potential Game-Changer? - TipRanks
Amgen’s Apremilast Study: A Potential Game-Changer for Pediatric Behçet’s Disease - TipRanks
Amgen’s CodeBreaK 202: A New Frontier in Lung Cancer Treatment - TipRanks
Amgen’s Innovative Study on AMG 193: A Potential Game-Changer in Cancer Treatment - TipRanks
Amgen Inc. stock daily chart insights2025 Big Picture & Technical Confirmation Alerts - newser.com
Amgen’s AMG 509 Study: A Potential Game-Changer in Prostate Cancer Treatment - TipRanks
Amgen’s Romiplostim Study: A Potential Game-Changer for Cancer Treatment - TipRanks
Amgen’s Latest Clinical Study Update: A New Hope for Small Cell Lung Cancer? - TipRanks
Amgen’s Apremilast Study: A New Hope for Pediatric Patients - TipRanks
Amgen’s New Prostate Cancer Study: A Potential Game-Changer? - TipRanks
Amgen’s Phase 3 Study on Xaluritamig: A Potential Game-Changer in Prostate Cancer Treatment - TipRanks
Amgen’s New Study on Xaluritamig: A Potential Game-Changer in Prostate Cancer Treatment? - TipRanks
Amgen’s Prolia Study: A New Horizon for Male Osteoporosis Treatment in China - TipRanks
Amgen’s Promising Study on Romosozumab for Osteogenesis Imperfecta: A Potential Game-Changer - TipRanks
Amgen’s AMG 355 Study: A Potential Game-Changer in Oncology? - TipRanks
Amgen’s Promising Phase 3 Study on Metastatic Colorectal Cancer - TipRanks
Amgen’s Phase 2 Study on Tarlatamab: A Potential Game-Changer for SCLC Treatment - TipRanks
Amgen’s Pediatric NMOSD Study: A Potential Game-Changer? - TipRanks
Amgen’s Maridebart Cafraglutide: A New Hope for Cardiovascular Health? - TipRanks
Amgen’s Repatha® Study: A Potential Game-Changer in Cardiovascular Care - TipRanks
Amgen’s Latest Clinical Study: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Amgen’s AMG 193 Study: A Potential Game-Changer in Thoracic Tumor Treatment - TipRanks
Amgen’s Prolia® Study: A New Frontier in Osteoporosis Treatment - TipRanks
Amgen’s Sotorasib Study: A Real-World Evaluation in Chinese NSCLC Patients - TipRanks
Amgen’s Phase 3 Study on Rocatinlimab: A Potential Game-Changer for Prurigo Nodularis - TipRanks
Amgen’s New Diabetes Study: A Potential Game-Changer? - TipRanks
Amgen’s Pediatric Psoriasis Study: A Potential Game-Changer in Dermatology - TipRanks
Amgen’s Latest Study: A New Contender in Lung Cancer Treatment? - TipRanks
Amgen’s AMG 193 Study: A New Hope for Advanced NSCLC Treatment? - TipRanks
Amgen Inc (AMGN) 財務データ
収益
当期純利益
現金流量
EPS
1.76%
大文字化:
|
ボリューム (24 時間):